Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Soo Young Kim, Seok‐Mo Kim, Hojin Chang, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Anlotinib as a molecular targeted therapy for tumors (Review)
Yi Gao, Pengfei Liu, Ruihua Shi
Oncology Letters (2020) Vol. 20, Iss. 2, pp. 1001-1014
Open Access | Times Cited: 118
Multikinase Inhibitor Treatment in Thyroid Cancer
Ole Vincent Ancker, Marcus Krüger, Markus Wehland, et al.
International Journal of Molecular Sciences (2019) Vol. 21, Iss. 1, pp. 10-10
Open Access | Times Cited: 109
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
Marcia S. Brose, Y. Panaseykin, Bhavana Konda, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 3, pp. 776-787
Open Access | Times Cited: 55
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Mijin Kim, Meihua Jin, Min Ji Jeon, et al.
Thyroid (2022) Vol. 33, Iss. 1, pp. 91-99
Closed Access | Times Cited: 32
Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
Shiting Li, Hongqin Wang
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 3429-3437
Open Access | Times Cited: 13
Olanzapine for managing side effects from antiangiogenic tyrosine-kinase inhibitors
Regina M. Koch, Miguel Muniz, Candy S. Peskey, et al.
Journal of Pain and Symptom Management (2025)
Closed Access
Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
Mengfei Cheng, Fang Yang, Jiahui Liu, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 24
Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life
Vincenzo Marotta, Domenico Rocco, Anna Crocco, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 10, pp. 2541-2552
Open Access | Times Cited: 3
Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival
Simone De Leo, Marta Di Stefano, Luca Persani, et al.
Endocrine (2020) Vol. 72, Iss. 2, pp. 462-469
Closed Access | Times Cited: 25
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
Ilario Giovanni Rapposelli, Shigeo Shimose, Takashi Kumada, et al.
ESMO Open (2021) Vol. 6, Iss. 4, pp. 100190-100190
Open Access | Times Cited: 18
Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event
Salvatore Monti, Federica Presciuttini, Maria Grazia Deiana, et al.
Thyroid (2021)
Open Access | Times Cited: 15
Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis
Judy Qiang, Raad Alwithenani, Elizabeth Uleryk, et al.
Thyroid (2022) Vol. 33, Iss. 2, pp. 192-202
Closed Access | Times Cited: 10
Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer
Dong Yun Lee, Yong-il Kim
Clinical Nuclear Medicine (2020) Vol. 45, Iss. 8, pp. 604-610
Closed Access | Times Cited: 15
Personalized treatment for differentiated thyroid cancer: current data and new perspectives
Carla Colombo, Noemi Giancola, Laura Fugazzola
Minerva Endocrinology (2021) Vol. 46, Iss. 1
Closed Access | Times Cited: 13
Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature
Liyong Zhang, Shao‐Jun Cai, Bo-Yan Liang, et al.
World Journal of Clinical Cases (2023) Vol. 11, Iss. 12, pp. 2839-2847
Open Access | Times Cited: 4
Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm
Carla Colombo, Daniele Ceruti, Simone De Leo, et al.
European Thyroid Journal (2023) Vol. 12, Iss. 4
Open Access | Times Cited: 4
Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated Thyroid Cancer: A Retrospective Study on a Korean Population
Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, et al.
Endocrinology and Metabolism (2024) Vol. 39, Iss. 2, pp. 310-323
Open Access | Times Cited: 1
Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer
Fernando Jerkovich, Soledad Capalbo, Erika Abelleira, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 817-826
Open Access | Times Cited: 1
Hand–foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer
Elisa Minaldi, Virginia Cappagli, Loredana Lorusso, et al.
European Thyroid Journal (2024) Vol. 13, Iss. 4
Open Access | Times Cited: 1
Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update
Alice Nervo, Francesca Retta, Alberto Ragni, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 168, pp. 103533-103533
Closed Access | Times Cited: 10
Daily Management of Patients on Multikinase Inhibitors’ Treatment
Carla Colombo, Simone De Leo, Matteo Trevisan, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 7
Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN
Sankha Bhattacharya, Satyam Sharma, Bhupendra G. Prajapati
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 6
Fournier's gangrene during lenvatinib treatment: A case report
Martina Barone, Giorgio Grani, Valeria Ramundo, et al.
Molecular and Clinical Oncology (2020)
Open Access | Times Cited: 7
Multikinase inhibitors for the treatment of radioiodine refractory thyroid cancer: what have we learned from the ‘real-world’ experience?
Giuseppe Costante
Current Opinion in Oncology (2020) Vol. 33, Iss. 1, pp. 3-8
Closed Access | Times Cited: 5
Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
Anne Christine Kaae, Michael C. Kreißl, Marcus Krüger, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12217-12217
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top